| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/28/2011 | CA2787476A1 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application |
| 07/28/2011 | CA2787365A1 Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| 07/28/2011 | CA2787318A1 Composition for perinatal and neonatal stroke |
| 07/28/2011 | CA2787248A1 Piperazine compound having a pgds inhibitory effect |
| 07/28/2011 | CA2787247A1 Novel composition |
| 07/28/2011 | CA2787184A1 Enterococcal cell wall components and antibacterial use thereof |
| 07/28/2011 | CA2787173A1 Methods and compositions for improved nerve conduction velocity |
| 07/28/2011 | CA2787156A1 Synthetic nanostructures including nucleic acids and/or other entities |
| 07/28/2011 | CA2787078A1 Methods for internally controlling or treating equine bot larvae |
| 07/28/2011 | CA2786866A1 Hydrogel of microspheres |
| 07/28/2011 | CA2786824A1 Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease |
| 07/28/2011 | CA2786762A1 Anaesthetic formulation |
| 07/28/2011 | CA2786730A1 5-(1h-pyrazol-5-yl)thiazole-based compounds for the treatment of diseases and disorders of the eye |
| 07/28/2011 | CA2786666A1 Novel compositions for reducing abeta 42 production and their use in treating alzheimer's disease (ad) |
| 07/28/2011 | CA2786568A1 Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
| 07/28/2011 | CA2786520A1 Pyrazine derivatives |
| 07/28/2011 | CA2786162A1 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds |
| 07/28/2011 | CA2785860A1 Gastroretentive solid oral dosage forms with swellable hydrophilic polymer |
| 07/28/2011 | CA2785624A1 Methods for producing amino-substituted glycolipid compounds |
| 07/28/2011 | CA2785521A1 Compositions including pyruvate for companion animals and methods of use thereof |
| 07/28/2011 | CA2785177A1 Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
| 07/28/2011 | CA2785173A1 Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| 07/28/2011 | CA2784807A1 Type ii raf kinase inhibitors |
| 07/28/2011 | CA2784587A1 Orally administrable film dosage forms containing ondansetron |
| 07/28/2011 | CA2782588A1 Nitrogen-containing heteroaryl derivatives |
| 07/27/2011 | EP2348134A1 RNA interference mediating small RNA molecules |
| 07/27/2011 | EP2348133A1 RNA interference mediating small RNA molecules |
| 07/27/2011 | EP2348118A1 A polynucleotide comprising a ubiquitous chromatin opening element (ucoe) |
| 07/27/2011 | EP2348115A2 Transgenic plant-based methods for plant pests using RNAi |
| 07/27/2011 | EP2348112A2 Stabilized immune modulatory RNA (SIMRA) compounds |
| 07/27/2011 | EP2348032A2 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 07/27/2011 | EP2348031A2 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents |
| 07/27/2011 | EP2348030A2 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents |
| 07/27/2011 | EP2348025A1 Nfat signal inhibitor and hair-growing agent |
| 07/27/2011 | EP2348024A2 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| 07/27/2011 | EP2348023A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| 07/27/2011 | EP2348021A1 Rotaxane compound and antitumor agent |
| 07/27/2011 | EP2348019A1 1,2-diazetidin-3-one derivative and pharmaceutical agent comprising same |
| 07/27/2011 | EP2348018A1 Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient |
| 07/27/2011 | EP2348016A1 Phenyl pyrrole aminoguanidine derivatives |
| 07/27/2011 | EP2347770A2 Process for producing an injectable pharmaceutical preparation |
| 07/27/2011 | EP2347768A1 Novel use application of sugar chain-recognizing receptor |
| 07/27/2011 | EP2347766A1 Use of TNFalpha antibodies and another drug |
| 07/27/2011 | EP2347759A2 Methods for controlling pests using RNAi |
| 07/27/2011 | EP2347758A1 Process for obtaining a composition of rosuvastatin calcium and product obtained |
| 07/27/2011 | EP2347757A1 A natural allicin tablet and preparation method thereof |
| 07/27/2011 | EP2347660A1 Composition for promoting control of total and ldl cholesterol and/or weight loss and/or thermogenesis |
| 07/27/2011 | EP2347654A1 Pesticidal formulations |
| 07/27/2011 | EP2347008A1 Methods and systems for improved pharmaceutical intervention in coagulation control |
| 07/27/2011 | EP2346926A1 Biologically active silicic acid |
| 07/27/2011 | EP2346896A1 Etoposide and doxorubicin conjugates for drug delivery |
| 07/27/2011 | EP2346882A1 Derivatives of 1-amino-2-cyclobutylethylboronic acid |
| 07/27/2011 | EP2346881A1 Novel compounds which modulate kinase activity |
| 07/27/2011 | EP2346878A1 Fused pyridine derivatives as kinase inhibitors |
| 07/27/2011 | EP2346876A1 Novel 4beta-amino podophvllotoxin congeners as anti tumour antibiotics a process for the preparation thereof |
| 07/27/2011 | EP2346875A1 Metalloporphyrin derivatives, nanoparticles comprising the same, and use thereof for photodynamic therapy |
| 07/27/2011 | EP2346874A1 Process for preparing chlorins and their pharmaceutical uses |
| 07/27/2011 | EP2346873A1 Azolopyrrolone melanin concentrating hormone receptor-1 antagonists |
| 07/27/2011 | EP2346872A1 Azolotriazinone melanin concentrating hormone receptor-1 antagonists |
| 07/27/2011 | EP2346871A1 Alpha helix mimetics in the treatment of cancer |
| 07/27/2011 | EP2346870A1 18f-labelled folates as pet radiotracers |
| 07/27/2011 | EP2346869A2 5-oxazolidin-2-one substituted 1,3,8-triazaspiro [4.5] decan-4-one derivatives useful as orl-1 receptor modulators |
| 07/27/2011 | EP2346868A1 Azaindazole compounds as ccr1 receptor antagonists |
| 07/27/2011 | EP2346866A1 Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
| 07/27/2011 | EP2346865A1 Indole derivatives as crth2 receptor antagonists |
| 07/27/2011 | EP2346864A1 Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| 07/27/2011 | EP2346863A2 N-sulfonamido polycyclic pyrazolyl compounds |
| 07/27/2011 | EP2346862A1 2-benzothiophenyl-and 2-naphthyl-0xaz0lidin0nes and their azaisostere analogues as antibacterial agents |
| 07/27/2011 | EP2346861A2 Thiophene containing analogues of fluconazole as antifungal agents and process thereof |
| 07/27/2011 | EP2346860A1 Pyrrolone melanin concentrating hormone receptor-1 antagonists |
| 07/27/2011 | EP2346859A1 Heterocyclic jak kinase inhibitors |
| 07/27/2011 | EP2346857A2 Compounds for the treatment of inflammatory disorders |
| 07/27/2011 | EP2346856A1 2-[1h-benzimidazol-2(3h)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3h)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors |
| 07/27/2011 | EP2346855A2 Process for making quinolone compounds |
| 07/27/2011 | EP2346853A2 Inhibitors of diacylglycerol acyltransferase |
| 07/27/2011 | EP2346852A1 Pyrrolidin-2-ones as hdm2 ligands |
| 07/27/2011 | EP2346848A1 Quinazoline derivatives as nk3 receptor antagonists |
| 07/27/2011 | EP2346846A1 Anhydrate and hydrate forms of strontium ranelate |
| 07/27/2011 | EP2346844A1 Substituted benzfurochromenes and related compounds for the prevention and treatment of bone related disorders |
| 07/27/2011 | EP2346843A2 Substituted benzamides as cannabinoid receptor ligands |
| 07/27/2011 | EP2346842A1 New amide compounds as boosters of antivirals |
| 07/27/2011 | EP2346841A2 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| 07/27/2011 | EP2346834A1 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives |
| 07/27/2011 | EP2346832A1 Tricyclic compounds as glutamate receptor modulators |
| 07/27/2011 | EP2346830A1 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| 07/27/2011 | EP2346829A1 Inhibitors of stat3 |
| 07/27/2011 | EP2346828A1 Piperazine derivatives used as cav2.2 calcium channel modulators |
| 07/27/2011 | EP2346827A1 Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
| 07/27/2011 | EP2346826A2 Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine |
| 07/27/2011 | EP2346825A2 Modulators of p2x3 receptor activity |
| 07/27/2011 | EP2346824A1 Novel estrogen receptor ligands |
| 07/27/2011 | EP2346820A1 Oxycarbamoyl compounds and the use thereof |
| 07/27/2011 | EP2346819A1 Naphthylacetic acids |
| 07/27/2011 | EP2346818A2 Substituted sulphonamido phenoxybenzamides |
| 07/27/2011 | EP2346817A1 Polymorphic form of calcium acamprosate |
| 07/27/2011 | EP2346814A2 Thyroid receptor ligands |
| 07/27/2011 | EP2346807A1 Naphthylacetic acids |
| 07/27/2011 | EP2346804A1 Compositions comprising cb receptor agonists, uses thereof and methods for their preparation |
| 07/27/2011 | EP2346573A2 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations |
| 07/27/2011 | EP2346550A1 Thermochemical ablation system using heat from delivery of electrophiles |